$0.47 Earnings Per Share Expected for Endo International plc (NASDAQ:ENDP) This Quarter
Wall Street analysts predict that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will report earnings of $0.47 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Endo International’s earnings, with the lowest EPS estimate coming in at $0.41 and the highest estimate coming in at $0.72. Endo International posted earnings per share of $0.74 in the same quarter last year, which would indicate a negative year over year growth rate of 36.5%. The firm is scheduled to issue its next quarterly earnings report after the market closes on Thursday, February 25th.
On average, analysts expect that Endo International will report full year earnings of $2.60 per share for the current year, with EPS estimates ranging from $2.53 to $2.75. For the next fiscal year, analysts anticipate that the firm will post earnings of $2.34 per share, with EPS estimates ranging from $2.13 to $2.63. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Endo International.
A number of equities analysts have recently weighed in on the company. SVB Leerink reiterated a “market perform” rating on shares of Endo International in a research note on Monday, February 8th. Piper Sandler increased their target price on Endo International from $6.00 to $12.00 and gave the stock an “overweight” rating in a research note on Monday, January 4th. Morgan Stanley increased their target price on Endo International from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Thursday, November 12th. Citigroup increased their target price on Endo International from $7.00 to $9.00 in a research note on Tuesday, January 19th. Finally, Zacks Investment Research lowered Endo International from a “buy” rating to a “sell” rating and set a $7.50 target price on the stock. in a research note on Tuesday, January 12th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Endo International currently has a consensus rating of “Hold” and a consensus price target of $6.92.
In related news, major shareholder International Plc Endo purchased 7,344,955 shares of Endo International stock in a transaction that occurred on Wednesday, December 2nd. The shares were acquired at an average price of $88.50 per share, with a total value of $650,028,517.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.50% of the company’s stock.
Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA grew its position in Endo International by 151.4% during the third quarter. BNP Paribas Arbitrage SA now owns 85,870 shares of the company’s stock worth $283,000 after buying an additional 51,717 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Endo International by 36.3% in the 3rd quarter. Victory Capital Management Inc. now owns 131,743 shares of the company’s stock valued at $435,000 after purchasing an additional 35,090 shares in the last quarter. Comerica Bank boosted its holdings in shares of Endo International by 11.0% in the 3rd quarter. Comerica Bank now owns 231,916 shares of the company’s stock valued at $1,343,000 after purchasing an additional 22,946 shares in the last quarter. New York State Teachers Retirement System boosted its holdings in shares of Endo International by 2.4% in the 4th quarter. New York State Teachers Retirement System now owns 321,383 shares of the company’s stock valued at $2,308,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new stake in shares of Endo International in the 4th quarter valued at $1,323,000. 79.98% of the stock is currently owned by institutional investors and hedge funds.
About Endo International
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine.
Featured Story: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.